Navigation Links
Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Date:11/24/2008

with PEGINTRON and REBETOL alone.

The study in treatment-naive patients is known as HCV SPRINT-2 and the study in patients who failed prior treatment is known as HCV RESPOND-2. The two studies are expected to enroll a total of more than 1,400 patients at U.S. and international sites.

For more information about these ongoing Phase III studies, please visit www.clinicaltrials.gov, search term boceprevir.

About Hepatitis C

Hepatitis C is a serious and potentially life-threatening disease. It is the most common blood-borne infection in America and Europe, and the most common form of liver disease, affecting nearly 5 million people in the United States, 5 million in Europe and some 200 million people worldwide. It is the leading cause of cirrhosis and liver cancer, and the number one reason for liver transplants in the United States and Europe.

About PEGINTRON

In the United States, PEGINTRON is indicated for use alone or with ribavirin for the treatment of chronic hepatitis C in patients with compensated liver disease who have not been previously treated with interferon alpha and who are at least 18 years of age.

Important Safety Information Regarding U.S. Labeling for PEGINTRON and REBETOL

Alpha interferons, including PEGINTRON and INTRON(R) A, may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Patients with persistently severe or worsening signs or symptoms of these conditions should be withdrawn from therapy. In many, but not all cases, these disorders resolve after stopping PEGINTRON and/or INTRON A therapy.

Use with Ribavirin: Ribavirin may cause birth defects an
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
2. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
3. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
4. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
5. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
6. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
7. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
8. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
9. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
10. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
11. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 As health officials across the ... select Meijer pharmacies in Michigan will ... eligible patients, enabling Meijer pharmacists to administer tests and, in ... by a physician participating in the study. The ...
(Date:1/15/2014)... Corporation (the "Company") (NASDAQ: CLSN ) today ... to purchase an aggregate of approximately $15 million of ... offering, led by a dedicated health care fund. ... these investors pursuant to which the Company agreed to ...
(Date:1/15/2014)... 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will receive ... Journal of Drugs in Dermatology (JDD) at the ... event is January 17-20, 2014, at the Omni Orlando Resort at ... The ODAC is a distinguished event that delivers ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... division of Wyeth (NYSE: WYE ), today ... has granted Fast Track designation,to the Company,s investigational ... is seeking a pediatric indication for,active immunization against ... serotypes included in the vaccine. The vaccine includes ...
... Targeting a Cure, WASHINGTON, May 28 ... join meso patients, caregivers,loved ones and advocates to ... at the Mesothelioma Applied Research Foundation,s,International Symposium on ... 28 at the Hyatt Regency on Capitol Hill, ...
Cached Medicine Technology:Wyeth Receives FDA Fast Track Designation for its 13-valent Pneumococcal Conjugate Vaccine for Infants and Toddlers 2Wyeth Receives FDA Fast Track Designation for its 13-valent Pneumococcal Conjugate Vaccine for Infants and Toddlers 3Wyeth Receives FDA Fast Track Designation for its 13-valent Pneumococcal Conjugate Vaccine for Infants and Toddlers 4International Symposium on Malignant Mesothelioma 2008 2
(Date:7/10/2014)... Adults with dyslexia are more likely to report that ... people who don,t have the learning disorder, according to ... to 10 percent of people, causes problems with reading ... with this condition said they suffered physical abuse during ... dyslexia. "Even after accounting for age, race, sex ...
(Date:7/10/2014)... News) -- Men who have a vasectomy may be ... study suggests. But the risk is comparatively small, ... the study said more research is needed to determine ... the study, Harvard researchers analyzed data from more than ... starting in 1986. During that time, 6,023 cases of ...
(Date:7/10/2014)... that the "Mississippi Baby," believed to have been functionally ... detectable levels of the virus, the Elizabeth Glaser Pediatric ... remains hopeful that the scientific breakthrough that allowed the ... two years will continue to help researchers understand how ... , "Although we had high hopes that the child ...
(Date:7/10/2014)... cells captured with a microchip-based device developed at the ... and the MGH Cancer Center can be cultured to ... In the July 11 issue of Science ... cells accurately reflect a tumor,s genetic mutation over time ... now can culture cells from the blood that represent ...
(Date:7/10/2014)... "Mississippi baby" an infant seemingly cured of HIV that ... of HIV infection in The New England Journal of ... more than two years of not taking antiretroviral therapy without ... researchers involved in the case. , "Certainly, this ... the medical staff involved in the child,s care, and the ...
Breaking Medicine News(10 mins):Health News:Researchers See Link Between Dyslexia, Abuse 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 3Health News:Despite setback, 'Mississippi Baby' represents significant breakthrough in effort to end AIDS 2Health News:Cultured CTCs reveal genetic profile, potential drug susceptibility of breast cancer cells 2Health News:Cultured CTCs reveal genetic profile, potential drug susceptibility of breast cancer cells 3Health News:'Mississippi Baby' now has detectable HIV, researchers find 2Health News:'Mississippi Baby' now has detectable HIV, researchers find 3
... , BREWER, Maine, Nov. 24 Thanks to an innovative ... Anthem Blue Cross and Blue Shield in Maine, some Anthem ... physician without leaving home. , As part of the ... and questions and communicate via email with their provider about ...
... pediatric cancer and hematology patients in medical rounds benefits ... a new Indiana University School of Medicine study. ... conducted, is now one of only a small number ... cancer and hematology patients the opportunity to join their ...
... ... available to discuss the recently proposed cosmetic surgery tax. , ... Arlington Heights, IL (Vocus) November 24, 2009 ... available to discuss the recently proposed cosmetic surgery tax., , ,WHAT: Some of ...
... strains have increased sevenfold, study finds, , TUESDAY, ... infections normally found in the community are increasingly ... that inpatients could become infected, new research says. ... sevenfold increase in the incidence of outpatients with ...
... New York personal injury ... attorney after a heavy metal piece falls off a plane and lands in a local Long ... New York, NY (PRWEB) ... recent occurrence as a reminder that everyone should have the number of a personal injury attorney ...
... ... seminar series, new ways to train doctors in providing proven, non-surgical relief to millions ... ... ) announced the first three 2010 Frozen Shoulder Syndrome Diagnosis & Treatment seminar ...
Cached Medicine News:Health News:The Doctor Will See You Now. . .Online 2Health News:Involving family in medical rounds benefits both family and medical team 2Health News:Involving family in medical rounds benefits both family and medical team 3Health News:Involving family in medical rounds benefits both family and medical team 4Health News:Leading Plastic Surgery Experts Available to Discuss Proposed ,Cosmetic Surgery Tax 2Health News:MRSA Creeping Into Hospitals From the Outside 2Health News:MRSA Creeping Into Hospitals From the Outside 3Health News:A New York Neighborhood Gets Hit Hard When A Piece Breaks Off A Plane 2Health News:A New York Neighborhood Gets Hit Hard When A Piece Breaks Off A Plane 3Health News:OTZ Announces 2010 Frozen Shoulder Syndrome Seminar Schedule 2Health News:OTZ Announces 2010 Frozen Shoulder Syndrome Seminar Schedule 3
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
Gentle curve facilitates less traumatic removal from eye. Increased length ideal for myopic eyes...
Sleeve extends 3mm beyond end, .90mm (20G) probe, 1.4mm (17G) sleeve...
Ideal for short scleral tunnel and trabecular meshwork incisions...
Medicine Products: